Literature DB >> 22338378

Hearing outcome after gamma knife radiosurgery for vestibular schwannoma: a prospective Belgian clinical study.

C Delbrouck1, S Hassid, G Choufani, O De Witte, D Devriendt, N Massager.   

Abstract

INTRODUCTION: Leksel Gamma Knife (LGK) radiosurgery is a safe and efficient therapeutic approach for vestibular schwannoma (VS) with low side effects. The goal of radiosurgery is not necessarily to cause significant tumour necrosis or to obtain a complete radiographic response, but to halt the tumour's growth permanently through its biological elimination. The 2 major aims of radiosurgery for VS are long-term tumour control and functional hearing preservation. The purpose of this study is to report our experience with LGK radiosurgery in the management of VS and to evaluate the hearing preservation rate after a minimum one-year follow-up.
MATERIAL AND METHODS: Between January 2000 and January 2011, 415 patients with unilateral VS underwent LGK radiosurgery at the University Erasmus Hospital of Brussels. There were 349 patients with previously untreated VS (86 grade I, 96 grade II, 141 grade III, 9 grade IVa, 17 unknown grades, according to Koos) and 66 patients with post-operative residual tumour. All patients in our series underwent evaluation with high resolution neurodiagnostic imaging including computed tomography and magnetic resonance imaging, and clinical evaluation as well as audiological tests that included tonal and speech audiometries. The Gardner Robertson (GR) classification is used to report the results of this study. We identified 276 patients treated for VS with LGK, tested and retested with speech and tonal audiometries by the same team, and followed for a minimum of one year.
RESULTS: Before LGK, 144 patients had serviceable (85 GR class I and 59 GR class II) hearing; 95 (65.97%) of these patients had preservation of serviceable hearing (Pure tone average < or = 50 db and Speech discrimination > or = 50%) at minimum one-year audiological follow-up. It was observed that 44 of the 85 GR class I patients (51.76%) maintained their level of audition and 66 of these (74.64%) preserved serviceable hearing. In the 34 patients with preradiosurgery non-serviceable hearing (GR class III-IV) 25 of these patients (73.52%) maintained their hearing. The tumour was stable or declining in size in 90.44% of cases.
CONCLUSION: LGK radiosurgery provides excellent tumour control in vestibular schwannomas and has low toxicity even after long-term follow-up.

Entities:  

Mesh:

Year:  2011        PMID: 22338378

Source DB:  PubMed          Journal:  B-ENT        ISSN: 1781-782X            Impact factor:   0.082


  5 in total

1.  CyberKnife for Treatment of Vestibular Schwannoma: A Meta-analysis.

Authors:  Hossein Mahboubi; Ronald Sahyouni; Omid Moshtaghi; Kent Tadokoro; Yaser Ghavami; Kasra Ziai; Harrison W Lin; Hamid R Djalilian
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04-25       Impact factor: 3.497

2.  Fractionated Proton Beam Therapy for Acoustic Neuromas: Tumor Control and Hearing Preservation.

Authors:  Carolyn J Barnes; David A Bush; Roger I Grove; Lilia N Loredo; Jerry D Slater
Journal:  Int J Part Ther       Date:  2018-07-26

3.  Hearing Preservation after Low-dose Gamma Knife Radiosurgery of Vestibular Schwannomas.

Authors:  Ayako Horiba; Motohiro Hayashi; Mikhail Chernov; Takakazu Kawamata; Yoshikazu Okada
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-02-15       Impact factor: 1.742

4.  Frameless fractionated stereotactic radiosurgery for vestibular schwannomas: a single-institution experience.

Authors:  Sana D Karam; Alexander Tai; Alexis Strohl; Matthew K Steehler; Abdul Rashid; Gregory Gagnon; K William Harter; Ann K Jay; Sean P Collins; Jeffrey H Kim; Walter Jean
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

5.  Repeat Gamma Knife surgery for vestibular schwannomas.

Authors:  Sarah Lonneville; Carine Delbrouck; Cécile Renier; Daniel Devriendt; Nicolas Massager
Journal:  Surg Neurol Int       Date:  2015-09-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.